<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02786979</url>
  </required_header>
  <id_info>
    <org_study_id>DorDM002</org_study_id>
    <nct_id>NCT02786979</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients</brief_title>
  <official_title>Combination of Beraprost Sodium Tablets (Dorner) and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective was to evaluate the efficacy and safety of combination of beraprost and aspirin
      for prevention of arteriosclerosis progress in type 2 diabetes mellitus patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Upon interim analysis, sponsor's decision due to absence of demonstration of efficacy.
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in carotid intima-media thickness</measure>
    <time_frame>Baseline to Year 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by vital signs: body temperature</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by vital signs: pulse rate</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by vital signs: respiratory rate</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by vital signs: blood pressure (systolic blood pressure and diastolic blood pressure)</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal laboratory values and/or adverse events related to treatment</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death rate</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of any vascular event</measure>
    <time_frame>Baseline to Year 3</time_frame>
    <description>Vascular events include sudden death, death caused by the vascular event, non-fatal coronary hear disease (CHD), non-fatal cerebrovascular diseases, and non-fatal aorta and peripheral artery disease (PAD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Ankle-brachial index</measure>
    <time_frame>Baseline to Year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Pulse wave velocity</measure>
    <time_frame>Baseline to Year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Oxidative stress indices</measure>
    <time_frame>Baseline to Year 3</time_frame>
    <description>Oxidative stress indices: superoxide dismutase and nitrotyrosine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in value of VCAM-1</measure>
    <time_frame>Baseline to Year 3</time_frame>
    <description>VCMA-1: vascular cell adhesion molecule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in value of TNF-α</measure>
    <time_frame>Baseline to Year 3</time_frame>
    <description>TNF: tumor necrosis factor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Beraprost sodium tablet and Aspirin combination group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beraprost</intervention_name>
    <description>Oral</description>
    <arm_group_label>Beraprost sodium tablet and Aspirin combination group</arm_group_label>
    <other_name>Dorner (R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Oral</description>
    <arm_group_label>Beraprost sodium tablet and Aspirin combination group</arm_group_label>
    <arm_group_label>Aspirin Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed as type 2 diabetes mellitus;

          -  Patients who had the intima-media thickness (IMT) of carotid artery ≥1.1 mm in at
             least one side;

          -  Patients who had results of aspartate aminotransferase, alanine aminotransferase, and
             serum creatinine no more than 1.5 times higher than the upper limit of normal;

          -  Patients who had not cardio or cerebral vascular events within 3 months, including
             non-fatal myocardial infarction, stable and unstable angina pectoris, and non-fatal
             cerebral ischemic and hemorrhagic stroke;

          -  Patients who had their systolic blood pressure &lt;160 mmHg, diastolic blood pressure
             &lt;100 mmHg, and glycated hemoglobin (HbA1c) &lt;8.0%;

          -  Patients who had not taken any medications with antithrombotic and antiplatelet effect
             within 3 months;

        Exclusion Criteria:

          -  Patients who had peptic ulcer or active alimentary tract hemorrhage;

          -  Patients who had a known allergy to prostacycline or non-steroid medications;

          -  Patients who were pregnant, breast feeding, or had planned to be pregnant;

          -  Patients who were attending or had attended any clinical studies within 3 months;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site CN00001</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00002</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00004</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00003</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00005</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CN00006</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>June 17, 2016</last_update_submitted>
  <last_update_submitted_qc>June 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Arteriosclerosis</keyword>
  <keyword>beraprost</keyword>
  <keyword>Aspirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Beraprost</mesh_term>
    <mesh_term>Epoprostenol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

